Aerie Pharmaceuticals
AERI
AERI was delisted on the 18th of November, 2022.
176 hedge funds and large institutions have $2.96B invested in Aerie Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 75 increasing their positions, 45 reducing their positions, and 25 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 45
66% more call options, than puts
Call options by funds: $26.2M | Put options by funds: $15.8M
4% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 25
1% more funds holding
Funds holding: 175 → 176 (+1)
0% more capital invested
Capital invested by funds: $2.94B → $2.96B (+$11.6M)
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$88.8M |
| 2 |
DM
Deerfield Management
New York
|
+$67.9M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$30.8M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$28.1M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$18.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$42.7M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$29.7M |
| 3 |
PC
PointState Capital
New York
|
-$19M |
| 4 |
HM
HealthCor Management
New York
|
-$18.1M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$9.64M |
AERI Hedge Fund Activity: Q3 2018 in Review
176 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Aerie Pharmaceuticals (AERI) for Q3 2018, worth a combined $2.96B — up 0.39% from $2.94B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new AERI positions and 25 closed out — a net gain of 1 holder — while 75 added to existing stakes and 45 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $88.8M. The largest seller was OrbiMed, cutting an estimated $42.7M.
- 176 institutional investors held Aerie Pharmaceuticals (AERI) as of Q3 2018, up from 175 in Q2 2018.
- Funds reported $2.96B of Aerie Pharmaceuticals stock for Q3 2018, up 0.39% quarter-over-quarter.
- 26 funds opened new Aerie Pharmaceuticals positions in Q3 2018 and 25 closed out, a net change of +1 holder.
- The largest Aerie Pharmaceuticals buyer in Q3 2018 was Citadel Advisors, an estimated $88.8M added.
- The largest Aerie Pharmaceuticals seller in Q3 2018 was OrbiMed, an estimated $42.7M sold.
Based on aggregated 13F filings for Q3 2018.